June 2nd 2023
In a phase 3 study, imetelstat has shown prolonged transfusion independence and hemoglobin increase in the relapsed or refractory myelodysplastic syndrome population.
May 26th 2023
Results from the phase 3 COMMANDS study were presented in a press briefing ahead of the 2023 ASCO Annual Meeting.
May 22nd 2023
The FDA has approved avapritinib for adult patients with indolent systemic mastocytosis based on findings from the phase 2 PIONEER trial.
May 19th 2023
A phase 3 trial evaluating roxadustat for the treatment of anemia in patients receiving concurrent chemotherapy for non-myeloid malignancies met its primary end point.
May 12th 2023
The proportion of patients with myelodysplastic syndromes who achieved red blood cell transfusion independence in the first 28 weeks was 47.5% for patients given roxadustat vs 33.3% for patients given placebo for the treatment of anemia.
2 Clarke Drive Cranbury, NJ 08512